Genetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer.

doi:10.1080/07853890.2025.2557510

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer.

Annals of medicine - 1 Dec 2025

Wu Yifan, Wang Yaohui, Sheng Xiaonan, Lin Yanping, Zhou Liheng, Lu Jinsong, Yin Wenjin

Abstract excerpt

PURPOSE: We conducted a retrospective exploratory analysis of prospective cohort to investigate the impact of CYP2A6 metabolizer status on predicting the efficacy and prognosis of neoadjuvant chemotherapy combined with letrozole. METHOD: Three allelic variants that related to the abolished or reduced activity of CYP2A6 enzyme and 7 other single nucleotide polymorphisms (SNPs) in the CYP2A6 locus were examined...

Read the complete abstract on PubMed

Topics

Humans
Letrozole
Female
Breast Neoplasms
Neoadjuvant Therapy
Middle Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Retrospective Studies

Cytochrome P-450 CYP2A6

Adult

Polymorphism, Single Nucleotide

Aged

Prognosis

Antineoplastic Combined Chemotherapy Protocols

Prospective Studies

Genotype

Treatment Outcome

Receptors, Estrogen

Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 40958617
DOI: 10.1080/07853890.2025.2557510
PMCID: PMC12444925

Genes

CYP2A6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer.PMID 40958617Read ↗

The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.Semantic proximity Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.Semantic proximity Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Semantic proximity Read ↗

Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.